Featured Archives - BaseLaunch

Cimeio collaborating with the University of Pennsylvania

Cimeio Therapeutic, headquartered in Basel with a subsidiary located in Cambridge, Massachusetts, is to carry out further research and evaluate its novel, universal immunotherapy for…

lenka18.10.2023

All Featured Portfolio news

Salvina Therapeutics joins BaseLaunch portfolio

Salvina Therapeutics AG, a recently founded Swiss company, is developing new therapies to break efficacy ceilings in inflammatory and autoimmune diseases. The company has unlocked…

lenka02.10.2023

All Featured Portfolio news

TOLREMO therapeutics secures USD 39 million

Basel, 20 September, 2023 – The Swiss biotech company TOLREMO therapeutics AG recently completed a successful Series A financing, bringing the total amount raised to…

lenka21.09.2023

All Featured Portfolio news

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

We are pleased to announce that Alentis Therapeutics, a company within our portfolio, has been granted fast track designation by the US FDA for its…

isabelletaureck13.09.2023

All Featured Portfolio news

Versameb strengthens its Board of Directors

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…

Martyna Wroblewska12.07.2023

All Featured Portfolio news

Cimeio Therapeutics and Prime Medicine announce research collaboration

Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…

Martyna Wroblewska22.06.2023

All Featured Portfolio news

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…

Martyna Wroblewska12.05.2023

All Featured Portfolio news

Phialogics closed a €600k pre-seed financing round with HTGF

Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…

Martyna Wroblewska21.04.2023

All Featured Portfolio news

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

Martyna Wroblewska21.04.2023

All Featured Portfolio news

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

Martyna Wroblewska30.11.2022

Featured

Cimeio collaborating with the University of Pennsylvania

Salvina Therapeutics joins BaseLaunch portfolio

TOLREMO therapeutics secures USD 39 million

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

Versameb strengthens its Board of Directors

Cimeio Therapeutics and Prime Medicine announce research collaboration

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics closed a €600k pre-seed financing round with HTGF

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us